ANIX•Anixa Biosciences said its breast cancer vaccine Phase 1 trial met all major endpoints. Of 35 patients dosed, 74% showed a protocol-specified immune response, and no safety concerns were reported.
Anixa Biosciences completed its breast cancer vaccine Phase 1 trial, with Phase 2 enrollment as the next milestone. The company said combining the vaccine with Keytruda produced no additional adverse effects. Lira-cel remains in Phase 1 for ovarian cancer, with periodic data releases tied to enrollment.
Anixa reported $14 million in cash and short-term investments and no debt as of July 31, 2026. Its cash burn was $7 million in the last fiscal year.
